BioLife Solutions, Inc. reaffirmed 2023 revenue guidance for the fiscal 2023. For the period, the company expects revenue to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.72 USD | +2.99% | -1.09% | +33.66% |
13/05 | Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target | MT |
09/05 | Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.66% | 100Cr | |
-5.56% | 18TCr | |
-0.11% | 11TCr | |
-6.17% | 6.61TCr | |
+2.64% | 5.07TCr | |
+6.58% | 4.31TCr | |
+4.91% | 4.13TCr | |
+21.98% | 3.16TCr | |
+14.45% | 2.5TCr | |
-5.81% | 2.42TCr |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- Biolife Solutions, Inc. Reaffirms 2023 Revenue Guidance for the Fiscal 2023